How does IZTC's PB Ratio compare to its peers?

IZTC has negative equity and a Price-To-Book Ratio (-31.2x) compared to the peer average (1.2x).

How does IZTC's PB Ratio compare vs other companies in the US Biotechs Industry?

IZTC has negative equity and a Price-To-Book Ratio (-31.2x) compared to the US Biotechs industry average (1.9x).

What is IZTC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate IZTC's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of IZTC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate IZTC's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Invizyne Technologies (Nasdaq:IZTC) - Stock Price, News & Analysis

IZTC Stock Overview

Operates as a synthetic biochemical company in the United States. More details

IZTC fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Revenue has declined by 100.7% over the past year

Has less than 1 year of cash runway

Makes less than USD$1m in revenue ($-700)

Shares are highly illiquid

+ 1 more risk

Invizyne Technologies, Inc. Competitors

Vigil Neuroscience

NasdaqGS:VIGL

US$122.9m

Decibel Therapeutics

NasdaqGS:DBTX

US$124.3m

Kinnate Biopharma

NasdaqGS:KNTE

US$125.1m

Skye Bioscience

NasdaqGM:SKYE

US$124.4m

Price History & Performance

Summary of all time highs, changes and price drops for Invizyne Technologies
Historical stock prices
Current Share Price	US$13.84
52 Week High	US$19.37
52 Week Low	US$8.50
Beta	0
11 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	60.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	IZTC	US Biotechs	US Market
7D	6.5%	4.0%	2.0%
1Y	n/a	18.0%	32.4%

Return vs Industry: Insufficient data to determine how IZTC performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how IZTC performed against the US Market.

Price Volatility

Is IZTC's price volatile compared to industry and market?
IZTC volatility
IZTC Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	3.1%

Stable Share Price: IZTC's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine IZTC's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2014	31	Michael Heltzen	www.invizyne.com

Invizyne Technologies, Inc. operates as a synthetic biochemical company in the United States. The company develops SimplePath, a platform that produces chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform also comprises one or more module which consist of one or more enzymes that work together to perform a defined biocatalytic conversion.

Invizyne Technologies, Inc. Fundamentals Summary

How do Invizyne Technologies's earnings and revenue compare to its market cap?
IZTC fundamental statistics
Market cap	US$120.28m
Earnings (TTM)	-US$5.12m
Revenue (TTM)	n/a

9,999x

P/S Ratio

-22.0x

P/E Ratio

Is IZTC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IZTC income statement (TTM)
Revenue	-US$700.00
Cost of Revenue	US$0
Gross Profit	-US$700.00
Other Expenses	US$5.12m
Earnings	-US$5.12m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.63
Gross Margin	100.00%
Net Profit Margin	731,989.29%
Debt/Equity Ratio	-122.6%

How did IZTC perform over the long term?

See historical performance and comparison